I worked as a writing analyst, and an Assistant Vice President, with Barclays Asia Equities coleading the consumer, retail and pharma sectors. I actively covered 30+ stocks (initiated on 24) over four years with a total market cap of $250bn+, along with a soft coverage of the mid-cap and unlisted companies. Apart from a strong relationship with corporate and industry partners, I was also been voted (both individually, as well as a 2-member team) by global funds across multiple sectors.
I published over 500 reports over the span of four years at Barclays Capital, both individually and in global collaboration. A small sample of the key reports below that were widely cited and discussed globally
Global Thematic Reports
Global Healthcare & Pharmaceuticals: US GX Market, a 3-Yr view: Pricing, Consolidation & Competition in focus
Global Healthcare & Pharmaceuticals: Craving for approvals: US FDA’s GDUFA performance analysis
Global Healthcare & Pharmaceuticals: Implications from the US Congressional Probe
Asia ex-Japan Equity Outlook: Where we differ
India Healthcare & Pharmaceuticals: Stay with pricing power; Lupin, DRL & Taro (Sun) take their $/Rx higher
India Healthcare & Pharmaceuticals: ‘The world is their oyster’ – Takeaways for Indian Pharma from our Healthcare trip
India Healthcare Trip Takeaways: Views from hospitals resonates with our urbanization theme
Asia ex-Japan Consumer: Five lessons in 13 years: investment pointers for Consumer stocks
India Consumer: Outlook for 2015 - Margin boost set to lift FMCG
India Consumer: Better days ahead: 10 themes from the Barclays India Consumer Trip
India Equity Strategy: India Budget An eye to the future
India Equity Strategy: When will earnings recover?
India Equity Strategy: Waiting for positive momentum
India Equity Strategy: Megatrends: India’s manufacturing – Exports poised for strong growth
Initiation Reports
Indian Consumer Discretionary | Indian Consumer Staples | Indian Auto Sector
Indian Pharmaceuticals | Indian Healthcare | Asian Healthcare
Average alpha generation of 32 / 50 percentage points 2 / 3 years post initiation
Stocks with a positive view outperformed the market index by 57 percentage points 3yrs post
Stocks with a negative view under-performed the market index by 32 percentage points 2yrs post
Strong non-consensus call on the negative view stock (45% buys vs 42% sells)
For a complete list of publications: see Complete List of Publications